Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

5.30USD
2 Dec 2016
Change (% chg)

$0.19 (+3.72%)
Prev Close
$5.11
Open
$5.11
Day's High
$5.35
Day's Low
$5.11
Volume
359,939
Avg. Vol
591,419
52-wk High
$6.45
52-wk Low
$2.51

SGYP.OQ

Chart for SGYP.OQ

About

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $1,000.54
Shares Outstanding(Mil.): 179.95
Dividend: --
Yield (%): --

Financials

  SGYP.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.23 -- --
ROI: -159.24 -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Synergy Pharma enters privately-negotiated exchange agreements

* Synergy Pharma-co entered privately-negotiated exchange agreements with certain holders of co's 7.50% convertible senior notes due 2019

Nov 21 2016

BRIEF-Synergy Pharmaceuticals Inc reports qtrly loss per share of $0.22

* Synergy Pharmaceuticals reports third quarter 2016 financial results and business update Source text for Eikon: Further company coverage:

Nov 09 2016

BRIEF-Synergy Pharma files for common stock offering of up to $17.2 million - sec filing

* Synergy Pharmaceuticals files for common stock offering of up to $17.2 million - Sec filing Source text for Eikon: Further company coverage:

Oct 06 2016

BRIEF-Synergy Pharmaceuticals announces new plecanatide data presentations

* Synergy Pharmaceuticals announces new plecanatide data presentations at upcoming scientific meeting and provides update on IBS-C program

Sep 28 2016

BRIEF-Synergy Pharma Q2 net loss $38.6 million

* Synergy pharmaceuticals reports second quarter 2016 financial results and business update

Aug 08 2016

BRIEF-Synergy Pharma updates on FDA review clinical development program

* Provides update on ongoing FDA review Of Plecanatide CIC NDA and IBS-C clinical development program

Jul 15 2016

Earnings vs. Estimates